ARTICLE | Finance
Lifting the Labrys against migraine
Pfizer spinout Labrys: Investors see best, first in class potential in migraine
January 7, 2013 8:00 AM UTC
Investors in Pfizer Inc. spinout Labrys Biologics Inc.'s $31 million series A round expect the newco's anti-CGRP mAb to be both best- and first-in-class for chronic migraine prophylaxis.
venBio led last week's round, with Canaan Partners, InterWest Partners and Sofinnova Ventures participating...